News

Oral JAK inhibitors are associated with measurable increases in lipid levels, emphasizing the need for vigilant cardiovascular monitoring during treatment.

At ACR 2025, early data of CTA313, a universal CD19/BCMA CAR-T therapy, demonstrate safety and strong responses in refractory lupus, offering hope for durable remission.

New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid arthritis flares and inflammation.

Persistent depression during adjuvant cancer therapy heightens treatment toxicity and significantly worsens overall QoL in early-stage cancer.

Repetitive head impacts and prior concussion can alter cortical microstructure in young athletes.

Stubborn lung infection can evolve within patients and develop traits that help it persist over time.

New research presented at ACR 2025 reveals IL-6 and CCL3 as predictive markers of fetal heart block in anti-Ro–positive pregnancies, paving the way for early detection and prevention.

Higher rifampicin exposure accelerated bacillary clearance and predicted pulmonary tuberculosis treatment outcomes in patients.